Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Potentia Pharmaceuticals Inc.

Division of Apellis Pharmaceuticals Inc.
www.potentiapharma.com

Latest From Potentia Pharmaceuticals Inc.

Is the Biotech IPO Window Closing?

Drug developers are filing for initial public offerings at a brisk pace in October despite falling biotechnology stock values and the struggle to price first-time offerings attractively, which begs the question: Are biotech companies afraid that the IPO window is about to close?

Gastrointestinal Cancer

BioNotebook: Shire moves jobs to Massachusetts as California asserts dominance; plus two deals, three financings

The Boston/Cambridge area – the center of the US East Coast biotechnology galaxy – sucked another company into its orbit recently with Shire announcing that it will relocate 500 employees from Chesterbrook, Pennsylvania to Lexington, Massachusetts.

Metabolic Disorders Gynecology & Urology

Hemera Biosciences Inc.

Overactive membrane attack complex (MAC) in retinal host tissue may underlie the development of the drusen fatty deposits characteristic of dry age-related macular degeneration and the leaky vasculature in the wet form of AMD, which can eventually blot out central vision. Hemera Biosciences Inc. is developing a single-injection gene therapy with the potential to rebalance the complement system in the retina and induce lifetime protection against disease progression for both wet and dry forms of AMD.

BioPharmaceutical

Imagen Biotech Inc.

With time to exit an increasingly important metric for VCs, jump-starting new companies via in-licensing remains an important and oft-used strategy. Such derisking is one of the defining principles behind Imagen Biotech, a new ophthalmic play still operating in stealth mode. Imagen plans to pursue new leads for sight-threatening diseases, including dry age-related macular degeneration.
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Apellis Pharmaceuticals Inc.
  • Senior Management
  • Cedric Francois, MD, PhD, Pres. & CEO
    Jason Slakter, MD, CMO
    Pascal Deschatelets, PhD, COO
    Paul Olson, PhD, CSO
  • Contact Info
  • Potentia Pharmaceuticals Inc.
    Phone: (502) 241-4114
    6400 Westwind Way
    Ste. A
    Crestwood, KY 40014
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register